AI-generated compounds hit specific cell types and outperform conventional screening
The classical drug discovery paradigm begins with a known molecular target: a protein whose modulation is expected to reverse the course of a disease. However, in many pathologies, such a target does not always exist or is not sufficiently characterized.
Image: Phys.org
The classical drug discovery paradigm begins with a known molecular target: a protein whose modulation is expected to reverse the course of a disease. However, in many pathologies, such a target does not always exist or is not sufficiently characterized.
Originally published at Phys.org
